Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4⁺ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial.

ABSTRACT: Background: A previous phase I/II study demonstrated potent and long-term immune responses in men with prostate cancer following vaccination with a 20mer synthetic peptide (RV001) derived from the Ras homolog gene family member C protein (RhoC). Moreover, a fraction of patients experienced prostate-specific antigen (PSA) responses, which prompted the initiation of a phase II double-blind randomized trial (NCT04114825). The primary endpoint was to study whether vaccination could postpone PSA progression. Furthermore, the study included an evaluation of vaccination-induced immune responses, and in-depth in vitro studies of RhoC-specific CD4⁺ T cell responses. Methods: Men with non-metastatic biochemical recurrence after either radical prostatectomy or radiation thera

SUBMITTER: Fresnillo Salo S 

PROVIDER: S-EPMC12031432 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature